Pcn326 - Comparative Analysis of Esmo Magnitude of Clinical Benefit Scale Values Assigned to NSCLC Cancer Drugs, Versus Real World Data on Prescribing Activity and Levels of Satisfaction in the Eu5

Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.408
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

ESMO - Magnitude of Clinical Benefit Scale V.1.0 Questions and Answers

ESMO Open
Cancer ResearchOncology
2016English

Detailed Statistical Assessment of the Characteristics of the ESMO Magnitude of Clinical Benefit Scale (ESMO-MCBS) Threshold Rules

ESMO Open
Cancer ResearchOncology
2017English

THU0503 Cost Analysis of Anti-Osteoporotic Drugs in Real-World Clinical Practice

2018English

Analysis of Real World Data to Evaluate Survival Benefit of Radiation Therapy in Stage III / N2 Non-Small Cell Lung Cancer

International Journal of Radiation Oncology Biology Physics
OncologyRadiologyCancer ResearchRadiationNuclear MedicineImaging
2019English

P3.01-106 Real-World Data to Evaluate the Clinical Benefit of NGS for Directing Lung Adenocarcinoma Treatment

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

The Risk/Benefit Profile of Biologic Drugs in Real-World Rheumatology Practice. From ANTARES to MonitorNet

Reumatismo
Rheumatology
2011English

P2.13-05 Real-World Clinical Benefit of Continuing Crizotinib Beyond Progression Disease (CBPD) in Patients With Advanced ALK-Positive NSCLC.

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

MS26.02 Translation of Clinical Data to Real World - North America

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

THU0474 Utilisation of Anti-Osteoporotic Drugs in Real-World Data: An Analysis of Persistence to Therapy and Risk of Fracture

2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy